The report titled “Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021)” provides a detailed analysis of the myasthenia gravis market with description of market size and growth. The analysis includes market size in terms of value, and market share on the basis of therapy, by cases and by severity.
- Agency -.
Scope of the Report
Complete report available at www.marketreportsonline.com/643473.html.
The report also provides a brief regional analysis of the US.
- Agency -.
Geographically, the Americas were the largest market and is expected to dominate the market in the forecasted period also. The growth in the market is estimated on the back of rising elderly population in the region.
Furthermore, the report also assesses the key opportunities available in the market and outlines the market dynamics that are and will be accountable for growth of the industry. Growth of the global myasthenia gravis market has also been forecasted for the period 2017-2021, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Some of the prominent players of the market include Avadel Pharmaceuticals, Hoffmann-La Roche, Pfizer, and Argenx. A brief company profiling of these major players have also been provided in the report on the basis of aspects like business overview, financial overview and business strategies adopted by respective companies.
Company Coverage: Avadel Pharmaceuticals, F. Hoffmann-La Roche, Pfizer & Argenx
Myasthenia gravis is a chronic neuromuscular disease that leads to weakness in the skeletal muscles, which help in the breathing and movement of the body parts including the arms and legs. The word ‘myasthenia gravis’ has Latin and Greek origin and means serious muscle weakness.
Myasthenia Gravis is rare and only affects 14 to 20 people out of every 100,000. The main symptom of myasthenia gravis is weakness in the voluntary skeletal muscles, which are muscles under one’s control.
Weakness associated with MG typically gets worse with more activity and improves with rest.
The disease is categorized into six types namely: Early-Onset MG, Late-Onset MG, Thymoma-Associated MG, MG with Anti-Musk Antibodies, Ocular MG, and MG with no detectable AChR and MuSK Antibodies. Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles.
Major treatments available for MG are Symptomatic Treatment, Rapid Short-Term Immune-Modulating Treatment, Chronic Long-Term Immune-Modulating Treatment and Surgery.
The global myasthenia gravis market has increased over the past few years and projections are made that the market would rise in the forecasted period i.e. 2017 to 2021 at a significant growth rate.
The global myasthenia gravis market is expected to boost by the major factors such as rising geriatric population, technological advancements, approval of monoclonal antibodies, strategies such as mergers and acquisitions. Yet the market growth is restrain by some challenges such as competition from off-label drugs, limited availability of FDA approved drugs, high cost of the treatment.
Key Topics Covered in Global Myasthenia Gravis Market:
- Executive Summary
- Global Market Analysis
- Regional Analysis
- Market Dynamics
- Competitive Landscape
- Company Profiling
Category: Market Research Publishers and RetailersCompany profile: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
For more information: